BioCentury | May 14, 2020
Finance

Daily Chart: Follow-on discounts during the pandemic

...At least three other companies have already completed follow-ons this week: Akebia Therapeutics Inc. (NASDAQ:AKBA), Protagonist Therapeutics Inc....
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...CEO. Previous portfolio companies include Cellular Research, which Becton Dickinson and Co. (NYSE:BDX) acquired, and Protagonist Therapeutics Inc....
BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

...Boulder, Colo.) appointed Steven Kafka, a partner at Third Rock Ventures, as executive chairman. Protagonist Therapeutics Inc....
...Wong and Chris Lieu, Staff Writers Alnylam Pharmaceuticals Inc. ArcherDx Audentes Therapeutics Inc. Black Diamond Therapeutics Inc. eTheRNA immunotherapies N.V. Gilead HeartFlow Inc. Protagonist Therapeutics Inc. Semma...
BioCentury | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

...deal Under an amended deal, Janssen Biotech Inc. will now have exclusive, worldwide rights from Protagonist Therapeutics Inc....
...1118, SHP606) Amgen Inc. BioNTech AG Chiesi Farmaceutici S.p.A. Jiangsu Hansoh Pharmaceutical Co. Ltd. Johnson & Johnson MabVax Therapeutics Holdings Inc. Novartis AG Protagonist Therapeutics Inc. Shire...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...South San Francisco, Calif.) hired Tom O'Neil as its first CFO. He was CFO at Protagonist Therapeutics Inc....
BioCentury | Aug 17, 2018
Clinical News

New Phase IIb analyses support further development of Protagonist's UC candidate

...antagonist, and the company plans to meet with FDA this half to discuss next steps. Protagonist Therapeutics Inc....
...score at week 12, pharmacokinetics and biomarkers Status: Final Phase IIb data Milestone: NA Jaime De Leon PTG-100 Protagonist Therapeutics Inc. Integrin...
BioCentury | May 25, 2018
Company News

Management tracks: ISA, ImCheck, ArQule

...development at Ariad Pharmaceuticals Inc., which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) acquired. Peptide therapeutic company Protagonist Therapeutics Inc....
BioCentury | Mar 30, 2018
Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

...PTG-300 to treat beta thalassemia, for which it has Orphan Drug designation in the U.S. Protagonist Therapeutics Inc....
...12, pharmacokinetics and biomarkers Status: Phase IIb discontinued Milestone: NA Jaime De Leon IL-23 receptor (PTG-200) PTG-100 PTG-300 Johnson & Johnson Protagonist Therapeutics Inc. Integrin...
BioCentury | Mar 26, 2018
Clinical News

Protagonist shares halved on UC failure

...for which it has Orphan Drug designation in the U.S. Jaime De Leon IL-23 receptor (PTG-200) PTG-100 PTG-300 Johnson & Johnson Protagonist Therapeutics Inc. Integrin...
BioCentury | Feb 28, 2018
Distillery Therapeutics

Cancer

...to treat psoriasis and have the compound in Phase III testing to treat psoriatic arthritis. Protagonist Therapeutics Inc....
Items per page:
1 - 10 of 38
BioCentury | May 14, 2020
Finance

Daily Chart: Follow-on discounts during the pandemic

...At least three other companies have already completed follow-ons this week: Akebia Therapeutics Inc. (NASDAQ:AKBA), Protagonist Therapeutics Inc....
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...CEO. Previous portfolio companies include Cellular Research, which Becton Dickinson and Co. (NYSE:BDX) acquired, and Protagonist Therapeutics Inc....
BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

...Boulder, Colo.) appointed Steven Kafka, a partner at Third Rock Ventures, as executive chairman. Protagonist Therapeutics Inc....
...Wong and Chris Lieu, Staff Writers Alnylam Pharmaceuticals Inc. ArcherDx Audentes Therapeutics Inc. Black Diamond Therapeutics Inc. eTheRNA immunotherapies N.V. Gilead HeartFlow Inc. Protagonist Therapeutics Inc. Semma...
BioCentury | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

...deal Under an amended deal, Janssen Biotech Inc. will now have exclusive, worldwide rights from Protagonist Therapeutics Inc....
...1118, SHP606) Amgen Inc. BioNTech AG Chiesi Farmaceutici S.p.A. Jiangsu Hansoh Pharmaceutical Co. Ltd. Johnson & Johnson MabVax Therapeutics Holdings Inc. Novartis AG Protagonist Therapeutics Inc. Shire...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...South San Francisco, Calif.) hired Tom O'Neil as its first CFO. He was CFO at Protagonist Therapeutics Inc....
BioCentury | Aug 17, 2018
Clinical News

New Phase IIb analyses support further development of Protagonist's UC candidate

...antagonist, and the company plans to meet with FDA this half to discuss next steps. Protagonist Therapeutics Inc....
...score at week 12, pharmacokinetics and biomarkers Status: Final Phase IIb data Milestone: NA Jaime De Leon PTG-100 Protagonist Therapeutics Inc. Integrin...
BioCentury | May 25, 2018
Company News

Management tracks: ISA, ImCheck, ArQule

...development at Ariad Pharmaceuticals Inc., which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) acquired. Peptide therapeutic company Protagonist Therapeutics Inc....
BioCentury | Mar 30, 2018
Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

...PTG-300 to treat beta thalassemia, for which it has Orphan Drug designation in the U.S. Protagonist Therapeutics Inc....
...12, pharmacokinetics and biomarkers Status: Phase IIb discontinued Milestone: NA Jaime De Leon IL-23 receptor (PTG-200) PTG-100 PTG-300 Johnson & Johnson Protagonist Therapeutics Inc. Integrin...
BioCentury | Mar 26, 2018
Clinical News

Protagonist shares halved on UC failure

...for which it has Orphan Drug designation in the U.S. Jaime De Leon IL-23 receptor (PTG-200) PTG-100 PTG-300 Johnson & Johnson Protagonist Therapeutics Inc. Integrin...
BioCentury | Feb 28, 2018
Distillery Therapeutics

Cancer

...to treat psoriasis and have the compound in Phase III testing to treat psoriatic arthritis. Protagonist Therapeutics Inc....
Items per page:
1 - 10 of 38